TABLE 1

Baseline Characteristics of Subjects at the Time They Received the First Dose of HPV4 Vaccine

EVG (n = 1179)CVG (n = 482)
Gender, n (%)
 Female614 (52.1)262 (54.4)
 Male565 (47.9)220 (45.6)
Age (y)
 Mean (SD)11.9 (1.9)14.5 (1.9)
 Median (range)12 (9 to 16)15 (11 to 18)
Region, n (%)
 Asia-Pacific143 (12.1)60 (12.4)
 Europe317 (26.9)128 (26.6)
 Latin America210 (17.8)104 (21.6)
 Nordic23 (2.0)11 (2.3)
 North America486 (41.2)179 (37.1)
HPV serostatus, m/n (%)
 Positive to HPV6/11/16 or 1820/1157 (1.7)9/474 (1.9)
 Positive to HPV68/1155 (0.7)7/474 (1.5)
 Positive to HPV111/1155 (0.1)3/474 (0.6)
 Positive to HPV168/1154 (0.7)5/474 (1.1)
 Positive to HPV183/1156 (0.3)2/474 (0.4)
 Positive to exactly 1 type20/1157 (1.7)5/474 (1.1)
 Positive to exactly 2 types00
 Positive to exactly 3 types04/474 (0.8)
 Positive to exactly 4 types00
  • m/n, number of subjects with serology data for the indicated type/number of subjects with the indicated characteristic.